Genomic determinants of common long-term treatment effects in childhood acute lymphoblastic leukemia survivors

儿童急性淋巴细胞白血病幸存者常见长期治疗效果的基因组决定因素

• 批准号: 234947
• 负责人: Sinnett Daniel
• 金额: $ 178.12万
• 依托单位: Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2011
• 资助国家: 加拿大
• 起止时间: 2011-06-01 至 2016-06-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=234947&lang=en
• 关键词: Biostatistics; Bone Morbidity; Cancer Survivorship; Cardiotoxicity; Childhood Leukemia; Long-Term Disease Outcomes/Biomarkers; Medical Genomics; Metabolic Syndrome; Neurocognition; Next-Generation Sequencing/Dna Variants

Acute lymphoblastic leukemia (ALL) is the most frequent cancer in children, accounting for approximately 25% of all pediatric tumors. Advances in our understanding of the pathobiology of this cancer and of its treatment have led to increased survival rate

急性淋巴细胞白血病 (ALL) 是儿童中最常见的癌症，约占所有儿童肿瘤的 25%。我们对这种癌症的病理学及其治疗的理解的进步导致了生存率的提高